EPS for Mallinckrodt Public Limited Company (MNK) Expected At $1.79

October 13, 2018 - By Ellis Scott

Investors sentiment decreased to 0.77 in Q2 2018. Its down 0.13, from 0.9 in 2018Q1. It dived, as 44 investors sold Mallinckrodt Public Limited Company shares while 90 reduced holdings. 48 funds opened positions while 55 raised stakes. 95.84 million shares or 0.62% less from 96.44 million shares in 2018Q1 were reported.
San Francisco Sentry Grp Inc (Ca) has invested 0% of its portfolio in Mallinckrodt Public Limited Company (NYSE:MNK). Ls Investment Advisors Limited Co accumulated 5,241 shares. Panagora Asset Mngmt Inc has 0.03% invested in Mallinckrodt Public Limited Company (NYSE:MNK) for 409,500 shares. Ubs Asset Mgmt Americas Inc stated it has 0% in Mallinckrodt Public Limited Company (NYSE:MNK). Legal General Grp Inc Public Ltd Limited Liability Company has 0% invested in Mallinckrodt Public Limited Company (NYSE:MNK) for 145,583 shares. Parametric Limited Liability Company has invested 0.01% of its portfolio in Mallinckrodt Public Limited Company (NYSE:MNK). Dimensional Fund Advsr Ltd Partnership reported 0.03% stake. D E Shaw owns 0% invested in Mallinckrodt Public Limited Company (NYSE:MNK) for 104,785 shares. Quantbot Technology Lp holds 0.01% of its portfolio in Mallinckrodt Public Limited Company (NYSE:MNK) for 9,492 shares. North Star Investment Management Corporation has invested 0% in Mallinckrodt Public Limited Company (NYSE:MNK). The New York-based Qs Ltd Limited Liability Company has invested 0% in Mallinckrodt Public Limited Company (NYSE:MNK). Winslow Evans Crocker stated it has 74 shares or 0% of all its holdings. Bnp Paribas Arbitrage invested in 0% or 163,050 shares. Commonwealth Of Pennsylvania School Empls Retrmt System, a Pennsylvania-based fund reported 22,426 shares. Great West Life Assurance Can has 98,343 shares.

Since May 9, 2018, it had 1 buying transaction, and 1 sale for $4.14 million activity. Flynn James E sold $4.19 million worth of Mallinckrodt Public Limited Company (NYSE:MNK) on Wednesday, May 9.

Analysts expect Mallinckrodt Public Limited Company (NYSE:MNK) to report $1.79 EPS on November, 6.They anticipate $0.18 EPS change or 9.14 % from last quarter’s $1.97 EPS. MNK’s profit would be $148.95 million giving it 3.79 P/E if the $1.79 EPS is correct. After having $1.78 EPS previously, Mallinckrodt Public Limited Company’s analysts see 0.56 % EPS growth. The stock increased 3.78% or $0.99 during the last trading session, reaching $27.16. About 1.58 million shares traded. Mallinckrodt Public Limited Company (NYSE:MNK) has declined 12.43% since October 14, 2017 and is downtrending. It has underperformed by 28.05% the S&P500.

Mallinckrodt Public Limited Company (NYSE:MNK) Ratings Coverage

Among 12 analysts covering Mallinckrodt (NYSE:MNK), 1 have Buy rating, 3 Sell and 8 Hold. Therefore 8% are positive. Mallinckrodt had 19 analyst reports since April 20, 2018 according to SRatingsIntel. The stock has “Hold” rating by Canaccord Genuity on Thursday, July 19. Leerink Swann maintained the stock with “Hold” rating in Monday, April 23 report. The rating was maintained by Mizuho with “Hold” on Friday, April 20. The company was downgraded on Wednesday, August 8 by Raymond James. FBR Capital maintained the shares of MNK in report on Thursday, June 28 with “Neutral” rating. The firm has “Hold” rating given on Wednesday, August 8 by Stifel Nicolaus. The company was maintained on Monday, June 18 by Stifel Nicolaus. The stock of Mallinckrodt Public Limited Company (NYSE:MNK) earned “Buy” rating by Cantor Fitzgerald on Tuesday, May 8. The firm has “Sell” rating given on Tuesday, September 11 by Goldman Sachs. Mizuho maintained it with “Hold” rating and $1500 target in Friday, May 18 report.

Mallinckrodt public limited company develops, makes, markets, and distributes branded and generic specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. The company has market cap of $2.26 billion. The company's Specialty Brands segment markets branded pharmaceutical products for autoimmune and rare diseases, including the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and hemostasis products, and central nervous system drugs. It has a 1.46 P/E ratio. This segment offers Acthar, an injectable drug for various indications, such as neurology, rheumatology, nephrology, and pulmonology; Ofirmev, an intravenous formulation of acetaminophen for pain management; Inomax for inhalation; Therakos, an immunotherapy treatment platform; and Exalgo, a form of hydromorphone.

More recent Mallinckrodt Public Limited Company (NYSE:MNK) news were published by: Benzinga.com which released: “Jefferies: Reaction In Mallinckrodt Shares To Praxair Competition Overblown” on October 05, 2018. Also Seekingalpha.com published the news titled: “FDA announces joint advisory committee review of Mallinckrodt’s Roxicodone” on October 08, 2018. Seekingalpha.com‘s news article titled: “Mallinckrodt down 17% on FDA nod for Praxair’s generic Inomax” with publication date: October 04, 2018 was also an interesting one.

Mallinckrodt Public Limited Company (NYSE:MNK) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>